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The characteristics of human resistin (RETN) are unclear and controversial despite intensive adipose-focused research. Its
transcriptional and functional similarity with the murine myeloid-specific and CCAAT/enhancer binding protein epsilon
(Cebpe)-dependent gene, resistin-like gamma (Retnlg), is unexplored. We examined the human CEBPE-regulatory pathway by
unbiased reference and custom gene expression assays. Real-time RT-PCR analysis demonstrated lack of both the
transcriptional factor CEBPE and RETN expression in adipose and muscle cells. In contrast, primary myelocytic samples
revealed a concerted CEBPE-RETN transcription that was significantly elevated in inflammatory synoviocytes relative to intact
peripheral blood mononuclear cells (PBMC). Mouse Cebpe and Retnlg were predictably expressed in macrophages, whereas
Retn was abundant in adipocytes. Quite the opposite, a low and inconsistent RETN transcription was seen in some human
white adipose tissue (WAT) biopsies without any relationship to body mass index, insulin sensitivity, or fat depot. However, in
these cases, RETN was co-detected with CEBPE and the leukocyte-specific marker, EMR1, indicating the presence of
inflammatory cells and their possible resistin-mediated effect on adipocytes. Indeed, addition of human resistin to WAT in
culture induced, like in PBMC, the inflammatory cytokines IL6, IL8 and TNF. Importantly, the expression of the adipose-specific
markers CEBPA, FABP4 and SLC2A4 was unchanged, while the expected inhibitory effect was seen with TNF. Both cytokines
increased the mRNA level of CCL2 and MMP3, which may further promote inflammation in WAT. Thus, the myeloid-restricted
nature of CEBPE precludes the expression of RETN in human adipocytes which, however, are targeted by this innate immune-
derived proinflammatory cytokine.
Citation: Nagaev I, Bokarewa M, Tarkowski A, Smith U (2006) Human Resistin Is a Systemic Immune-Derived Proinflammatory Cytokine Targeting
both Leukocytes and Adipocytes. PLoS ONE 1(1): e31. doi:10.1371/journal.pone.0000031
INTRODUCTION
Obesity is clearly associated with the development of insulin
resistance, diabetes and other metabolic and cardiovascular
disorders in man. An important mechanistic link between these
debilitating diseases and an increased fat mass is thought to be the
anomalous production by adipose cells of a group of diverse
effector molecules, collectively named adipocytokines. Like many
other assumptions, this hormonal or endocrine hypothesis was
primarily explored in mouse, although human genome and
physiology significantly diverge from the rodent settings. Recently,
mouse resistin was described as a novel obesity-mediated
adipocytokine that impairs glucose homeostasis by affecting both
insulin-stimulated glucose uptake in adipose tissue and hepatic
glucose production during fasting. However, there were initially
two opposite views on human resistin. Like in rodents, the human
homolog appears as an adipose-specific and obesity-regulated
antagonist of insulin action or, conversely, blood/immune cells
and not adipocytes are source of resistin.
Mouse resistin, official gene symbol Retn (Table 1), is also
known under other aliases depending on how it has been
identified. Holcomb et al. [1] discovered mouse Fizz3 and human
FIZZ3 by searching sequence databases for genes similar to the
novel murine gene Fizz1, found in inflammatory zone 1. Kim et al.
[2] named a new murine protein as solely adipose tissue-specific
secretory factor (ADSF) and Steppan et al. [3] called it resistin for
causing resistance to insulin. The mouse resistin like alpha (Retnla)
and beta (Retnlb) genes were also known at that time [1,4], while
one additional gene, resistin like gamma (Retnlg), was described
later [5,6]. So far, only two corresponding human genetic traits
have been variably recognized (Table 1), but registered as RETN
and RETNLB. These original reports [1–3] concordantly
highlighted that murine resistin is produced entirely by adipocytes,
but the source of human resistin remained unknown.
As frequently happens, the clarification came from another
field. The earliest annotation of the mouse Retnlg was provided in
accession BE847001 [7]. This novel gene for short cysteine-rich
protein 1 (homologous to FIZZ1) was not expressed in myeloid
cells from C/EBP-epsilon knockout mice. The myeloid-specific
nuclear transcription factor CCAAT/enhancer binding protein
epsilon (CEBPE) has been characterized previously [8]. The same
group also identified all resistin-related genes, which were named
as ten-cysteine-proteins (XCP) for their characteristic C-terminal
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Resistin (RETN) was defined in AF352730 as Homo sapiens C/
EBP-epsilon regulated myeloid-specific secreted cysteine-rich
protein precursor (HXCP1) gene. These findings as well as the
broadly accepted belief that human resistin, RETN, is homologous
to the murine counterpart Retn were tested in our earlier study of
the putative role of RETN as a factor involved in insulin resistance
[9]. We showed that RETN was readily expressed in monocytes.
However, RETN mRNA levels were low and unstably detected in
WAT while RETN transcript was totally absent in isolated
adipocytes and muscle samples from non-obese euglycemic but
insulin-resistant subjects. Therefore we, like others [10,11],
concluded that resistin in WAT and skeletal muscle is unrelated
to insulin action in man [9].
Firm evidence of the similarity between mouse resistin like
gamma, Retnlg/Xcp1, and human resistin, RETN/XCP1, was
recently published by Chumakov et al. [12]. Interestingly, the
expression of these genes was exclusively found in myeloid cells
with the highest level in bone marrow. Their transcription is
dependent on mouse Cebpe and human CEBPE [12]. The latter
appears vital for terminal differentiation and functional matura-
tion of human committed granulocyte progenitor cells [13]. In
both species, this myeloid transcription factor was shown to be
essential for, and co-expressed with, XCP1/RETN and Xcp1/
Retnlg. Furthermore, its functional disruption in either species
results in total silencing of RETN and Retnlg, whereas the
induction triggers their expression even in non-myeloid cells [12].
Additionally, released human resistin as well as mouse resistin like
gamma proteins play the same role in the chemotaxis of bone
marrow-derived myeloid cells and specifically interact with human
neutrophil a-defensin [12]. Taken together, these findings indicate
that human RETN is the biological analogue of murine Retnlg.
This widely disregarded dualism of human resistin, i.e., RETN
gene being a homologue of mouse Retn but a regulatory and
functional analogue of murine Retnlg, has led to discrepant and
controversial observations. All along, the mixed conception for
human resistin as an adipocyte- and macrophage-derived cytokine
with metabolic and inflammatory activities was a diffuse and
confusing paradigm. As a result, none of the basic investigations
and clinical trials could explicitly clarify which human cells
produce resistin and its physiological role. Adding to the difficulty,
resistin gene lineages have seemingly underwent various altera-
tions during the evolution of different mammalian species.
Therefore, in the present work, we tested all resistin regulatory,
functional and also emerging evolutionary concepts in different
human and mouse models aiming to explain the Resistin Paradox
decisively. Overall, in addition to previous studies [9,14], our new
findings strongly support the immune-specific role of human
resistin as a significant local and systemic modulator of in-
flammation.
RESULTS
Cell- and tissue-specific expression of human
resistin
We first examined if isolated human mature adipose cells, like
their murine counterparts, express resistin and/or the necessary
transcription factor CEBPE. For this purpose, we studied different
leukocytic specimens as positive controls together with human
WAT, preadipocytes and muscle as well as murine adipose cells
and macrophages (Table 2). Human cells were tested for CEBPE
and RETN as well as EMR1 (or murine alias F4/80), a leukocyte-
specific receptor which indicates the presence of white blood cells
in a sample. The transcription level of CEBPE was readily
detectable and RETN was also expressed in freshly prepared
PBMC and synoviocytes as well as in differentiated macrophages,
albeit at a lower level. In these myeloid samples we observed a clear
CEBPE-RETN correlation (R
2=0.4, p,0.006, n=9) and a lower,
but still significant, association between CEBPE and EMR1
(R
2=0.2, p,0.006, n=9). In contrast, THP-1 monocytes
displayed an apparent discrepancy with high expression of CEBPE
but not of RETN. Also, PBMC cultured for 24 hours revealed
a gradual decline in RETN transcription while the CEBPE
mRNA level remained almost unchanged. After the culture
period, the expression profiles in PBMC resembled that of THP-1
cells and in vitro differentiated macrophages (Table 2). Taken
together, these results show that freshly isolated human primary
inflammatory cells co-express CEBPE and RETN. However,
RETN expression decreases during culture while CEBPE remains
more stable.
In some freshly obtained ex vivo human WAT specimens,
CEBPE and RETN were detected with valid Ct values (Table 2).
However, their expression was unrelated to fat depot, body mass
index (BMI) or insulin resistance. Significantly, CEBPE and
RETN mRNA were co-detected with the EMR1 transcript
demonstrating that the expression of all these genes is limited to
Table 1. Different Resistin Gene Families in Mus musculus (Mm) and Homo sapiens (Hs)
..................................................................................................................................................
Reference R NCBI* (7, 12) (1) (3, 4) # (2) (5, 6)
Year R 2006 2000–2004 2000 2001 2000 2001 2003–2004
Chromosomal Gene Location Q Official Symbol Other Aliases Official Name
Mm 8 0.37 cM Retn Xcp4 Fizz3 resistin A12-alpha ADSF
Hs 19p13.2 RETN XCP1 FIZZ3 resistin A12-alpha-like 1 ADSF
Mm 16 32.6 cM Retnla Xcp2 Fizz1 RELMalpha A12-gamma
Mm 16 33.0 cM Retnlb Xcp3 Fizz2 RELMbeta A12-beta
Hs 3q13.1 RETNLB XCP2 FIZZ1 or 2 RELMbeta A12-alpha-like 2
Mm 16 32.5 cM Retnlg Xcp1 RELMgamma
*To avoid variant readings of any gene only official symbols and names (in bold) with species-specific spellings as provided by the HUGO Gene Nomenclature
Committee and the NCBI are operated in this work together with other aliases when appropriate.
#This alias is unpublished discovery of resistin gene family by Rajala MW and Scherer PE with proposal titles as Identification of a novel adipose-specific cysteine-rich
secreted protein & Identification of a novel cysteine-rich secreted A12-alpha related protein was supported by five sequences AF290870-74 submitted to the NCBI (28-
JUL-2000).
doi:10.1371/journal.pone.0000031.t001
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PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e31the myeloid cells present in a sample. This was further supported
by the finding that homogeneous cell populations of either human
preadipocytes or isolated subcutaneous adipocytes exhibited
predominantly undetermined Ct for all these genes. Thus, the
source of this low and variable expression of CEBPE and RETN
in human WAT is likely to be blood leukocytes and/or resident
macrophages - all EMR1-positive. Together, these results
corroborate that isolated human primary adipocytes and pre-
adipocytes do not express RETN or its transcriptional activator
CEBPE.
In contrast to these findings, Cebpe expression in mouse
peritoneal macrophages was co-localized with Retnlg, but not with
Retn transcription; the latter being solely restricted to adipose
specimens (Table 2). The basis of such disparity between these two
mammalian species, i.e., the differences seen between orthologous
resistin genes, combined with the obvious similarity of non-
homologous RETN and Retnlg, is presently unclear.
Re-examination of RETN expression by specifically
selected TaqMan real-time PCR assays
It is important to clarify the reason for the controversial results
produced by different authors regarding the expression of RETN
in human adipose samples using the same real-time RT-PCR
technique (see e.g., 9, 10 versus 11, 15, 16). Until recently, there
was no inter-laboratory reference test available, but we have now
compared one of three standard RETN Gene Expression Assays
developed by Applied Biosystems with other resistin TaqMan
constructs (Table 3) all-in-one-test. We purposely used the absolute
quantification or the standard curve method because only this
procedure firmly generates several key indices. The correlation
coefficient represents the accuracy of the standard curve where
a slope value around 23.5 means the highest PCR efficiency
(Table 4, Panel A). Together, they indicate the reliability of each
assay and also qualify the comparison between them (Table 4,
Panel B).
In general, all three FAM/VIC multiplexed assays have similar
detection effectiveness, while the fluctuations among Ct and slope
numerals (Table 4) are mostly attributable to the differences in
threshold and in ordinary set design including specific physico-
chemical qualities of the probe (see Methods and Table 3). The
data show that all assays are unable to detect RETN transcript in
isolated adipocytes (Table 4, Panel B). Likewise, they cannot
quantify it correctly in WAT and skeletal muscle even if Ct FAM
values were determined. These values are within the invalid
detection range from 35 to undetermined and significantly
scattered in a replica in contrast to the consistent Ct figures in
the blood and synovial samples. As a result, both inter-assay and
intra-replica variations are small (6.5 and 4.7%) in the myeloid
analyses versus the gross deviations (68 and 32%) in the adipose-
muscle assessments. The intra-assay endogenous 18S rRNA
control is also the inter-assay reference demonstrating a modest
8.4% divergence between all replicas, samples and assays. Thus,
the complete uniformity of the trial confirms the low to absent
detection level of RETN in human adipose tissue. In contrast,
synoviocytes from patients with rheumatoid arthritis show that
RETN expression is elevated at a site of inflammation (Tables 2
and 4).
We also investigated the potential expression of an alternatively
spliced variant of RETN with deletion of the entire exon 3
(RETND in Table 3) in the same one-plate-test. The copy number
of this molecule was extremely low with an approximate ratio of
1:240 of the truncated vs. full-length transcripts. This was only
possible to evaluate in PBMC (data not shown).
Altogether, these results demonstrate that neither alternative
splicing nor variations between real-time PCR assays, but rather
Table 2. Examination of Gene Expression in Basally Conditioned Tissue and Cell Cultures
..................................................................................................................................................
HUMAN GENE R CEBPE RETN EMR1
Adipose/muscle test Q Ct Ct Ct n=
WAT subcutaneous 35-UD 34-UD 32-UD 16
WAT omental 33-UD 34-UD 31-UD 9
Adipocytes subcutaneous UD 39-UD 36-UD 14
Preadipocytes subcutaneous UD UD UD 3
Muscle 38-UD 37-UD 35-UD 5
Myelocytic sample Q Ct RQ Ct RQ Ct RQ n=
PBMC 0 h 33–35 1.00 28–34 1.00 28–29 1.00 10
PBMC 0.5 h 33–34 0.69 29–30 0.48 na 3
PBMC 3 h 34–34 0.79 30–31 0.35 na 3
PBMC 24 h 33–33 0.90 33–35 0.01 na 3
Synoviocytes 31–34 2.51 29–34 3.32 28–32 0.63 7
Macrophages 34–37 0.10 35–38 0.02 33–34 0.01 5–6
THP-1 29–32 2.36 37-UD 0.00 32–34 0.02 3
MOUSE GENER MODEL Q Cebpe Retn Retnlg n=
WAT subcutaneous UD 27–28 UD 2
3T3-L1 UD 26–27 UD 3
Macrophages 29–32 UD 32–34 3
The lower the expression, the higher the threshold cycle (Ct) value excluding the invalid detection range from 35 and up to undetermined (UD) Ct if no amplification
occurs within 40 cycles. As a result, the expression of tested genes cannot be quantified in human adipose and muscle samples and this part of the data simply shown
as indicative Ct intervals obtained in different experiments. Conversely, the operable Ct figures in myeloid/synovial group were evaluated as relative quantities (RQ) with
the reference PBMC settings as 1 or 100%.
doi:10.1371/journal.pone.0000031.t002
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PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e31the high sensitivity of the method accounted for the detection of
even a few RETN-positive leukocytes, either peripheral blood cells
and/or the tissue-residing inflammatory cells, which were present
in some human WAT samples.
Proinflammatory effects of resistin in human
adipose tissue
As concluded above, resistin is not expressed in human primary
adipocytes but it is present in immune cells which are found in
subcutaneous WAT in obesity [17] and also infiltrate epicardial fat
depot in patients with coronary disease independent of BMI and
diabetes [18]. Consequently, human adipocytes may be target cells
for resistin. We investigated this possibility by exposing biopsies of
human WAT to a physiologically relevant [14] concentration of
resistin (50 ng/ml) or, as a positive control, 10 ng/ml of TNF for
24 hrs. As shown in Figure 1A (left), both cytokines induced
expression of several inflammatory molecules, although to
a different extent. TNF enhanced the expression of IL6 and IL8
79- and 44-fold, respectively, and its own gene about 3.4-fold.
Similarly, secretion of both IL6 and IL8 to the culture medium
was increased on average 28-times (Figure 1A, right). Resistin also
elevated both the mRNA level (17- and 4-fold) and protein
secretion (1.6- and 2.3-fold) of IL6 and IL8, while only a small
(2.6-fold) and insignificant stimulatory effect was seen on the TNF
gene (Figure 1A, left). Additionally, we found that resistin, similar
to TNF, induces the CCL2, MMP3 and PBEF1 genes, which are
all relevant to the inflammatory process in the adipose tissue
(Figure. 1B). Although both TNF and RETN exerted a proin-
flammatory action on the WAT explants, their effects on the
markers of adipose differentiation varied. As expected, TNF
reduced the expression of CEBPA, FABP4 and SLC2A4 (GLUT4)
by 40–70% while these genes remained unchanged upon exposure
to resistin at this concentration (Figure. 1C). Together, these
findings show that human adipocytes do not produce resistin but
they are target cells for this cytokine which, in analogy with TNF,
enhances the inflammatory process in adipose tissue.
DISCUSSION
Experimental human data regarding the nature of RETN-
expressing cells as well as the physiological role of secreted resistin
are controversial. In contrast to our own studies [9] and also those
from several other laboratories [10,12,19–24], McTernan et al.
[16] reported that resistin mRNA and protein could be recovered
from both isolated human pre-adipocytes and mature adipose
cells. Moreover, it was stated that RETN is differentially expressed
between various fat depots [15]. In both studies, a higher signal
was found in abdominal WAT suggesting that, similar to rodents,
resistin may connect central obesity to insulin resistance and
diabetes in man. Also, Degawa-Yamauchi et al. [25] detected
RETN protein in isolated adipocytes and observed a positive
association between serum resistin level and adiposity. Finally, in
the study by Janke et al. [11], human preadipocyte differentiation
was coupled with a declining gene expression. Although this
observation was corroborated by barely measurable mRNA levels
in primary cultured mature adipocytes, no link with insulin
resistance was found.
In contrast to these discrepant results, various investigations in
man consistently revealed the presence of resistin in myeloid cells:
both primary monocyte-derived and/or differentiated macro-
phages [9,10,19–21,26–28] as well as in primary acute leukemia
cells and the myelocytic lines U937 and HL60 [22]. This leukocyte
expression of human resistin was recently discovered to depend on
the myeloid-specific nuclear transcription factor CEBPE [12]. The
action of CEBPE was previously known to be restricted to the
haematopoietic tissues, especially myeloid granulocyte/macro-
phage and lymphoid T-cell lineages in the bone marrow
[8,13,29,30]. In line with, but independent of the CEBPE
research, the highest level of resistin was found in the bone
marrow [20,24]. Moreover, human resistin possesses diverse
immune activities such as induction of chemotaxis of myeloid
cells [12], as an inflammatory cytokine in rheumatoid arthritis [14]
and in endotoxemia [26], and as a macrophage-derived
atherogenic factor inducing endothelial dysfunction and vascular
smooth muscle cell migration [27].
Human RETN and mouse Retn genes are orthologs [22] and,
consequently, due to their evolutionary genetic relatedness,
thought to be homologous traits. Surprisingly, human resistin
exhibits characteristics which are clearly distinct from those of its
mouse counterpart Retn. Furthermore, RETN shares prominent
similarity with Retnlg [12], another resistin family member
identified only in rodents. This still unrecognized phenomenon
took place during evolution of other mammals, like cow and pig,
also expressing RETN in myeloid cells [31] rather than in adipose
tissue [31,32]. The current understanding of this discrepancy is
difficult since mouse and human resistin, nevertheless, exhibit
common arthritogenic [14] and atherogenic [33,34] features even
if they are produced by different cells.
In the present study, we carefully examined in which human
cells resistin is expressed and also focused on the CEBPE-RETN
transcriptional link and the putative immune/inflammatory action
in WAT. Consistent with Chumakov et al. [12], we found that
Table 3. Common Principle of the Over-Exon-Boundary
Location of Probe in Reference Gene Expression Assays (GEA)
and Primer(s) in our Custom Tests
......................................................................
Gene
Symbol
GEA Identification
Custom RETN Tests
a
GEA Probe
Location
Custom Test
Primer 59-end
Source
mRNA
Sequence
RETN Hs00220767_m1 220 AF205952
RETN RSTN
a 127–233 AF205952
RETN RES
a 129
b AF205952
RETN RETND
a 106 AB111910
CEBPE Hs00357657_m1 610 603 BC035797
EMR1 Hs00173562_m1 992 2404 X81479
IL6 Hs00174131_m1 390 258–401 M18403
IL8 Hs00174103_m1 169 283–398 Y00787
TNF Hs00174128_m1 366 306–380 M10988
CCL2 Hs00234140_m1 137 121 BC009716
MMP3 Hs00233962_m1 152 656 BC074815
PBEF1
c Hs00237184_m1 78/88 980/990 U02020/
BC020691
SLC2A4 Hs00168966_m1 180 1046–1176 M20747
CEBPA
d Hs00269972_s1 2017 1457 U34070
FABP4 Hs00609791_m1 131 294–419 J02874
aDescription of three RETN custom tests: 1) primers in our previous RSTN set (9)
overlap two consequent exon-exon junctions, which separately spanned by
different probes in 2) RES, a custom construct from another laboratory (15),
and in standard RETN GEA from Applied Biosystems; finally, 3) RETN? is our
design for the deletion variant of RETN mRNA (45).
b59-end of the probe.
cThe standard and custom constructs detect both currently known transcript
variants of PBEF1.
dThe assay location is not at exon junction because CEBPA is an intronless gene.
doi:10.1371/journal.pone.0000031.t003
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PLoS ONE | www.plosone.org 5 December 2006 | Issue 1 | e31RETN generally follows CEBPE expression. Both transcripts were
also determined to be attributes of myeloid cells because of the
stringent co-localization with EMR1, which appeared to be
a common leukocytic marker (Table 2) rather than an exclusive
macrophage determinant [35]. Therefore, it is essential to further
define the precise mechanism of RETN expression in particular
types of leukocytes present in blood and synovia as well as in
adipose tissue. We observed a clear discrepancy in expression of
the RETN and CEBPE genes in myeloid samples newly obtained
in vivo vs. the same cells conditioned in vitro. There was a high and
concomitant CEBPE-RETN expression in fresh blood and
synovial fluid specimens but a reduced and dissociated transcrip-
tion in cultured PBMC, macrophages and THP-1 cells. The latter
immortalized cells do not express RETN but visibly display
CEBPE as also corroborated by Northern blot analysis [12,13].
Nonetheless, very low CEBPE expression in macrophages, seen
here and by others [13], was yet accompanied by RETN
transcription, albeit at a low level (Table 2). Although the RETN
expression is under ultimate transcriptional control of CEBPE
[12], the activity of CEBPE is modified by phosphorylation [36],
heterodimerization with abundant associate proteins [37] and
a synergistic effect of MYB and ATF4 [12]. Other transcriptional
factors, like PPAR gamma [20], SP1 and SP3 [38] and also
SREBF1 [39], could influence the RETN regulation in vitro. The
role and activation of CEBPE is different during granulocytic and
monocytic differentiation [13]. Consequently, CEBPE-to-RETN
regulatory strength can change considerably upon various
conditions and in certain cell type (Table 2). Our results show
a higher expression level of both genes in synoviocytes, presumably
granulocytes, than in peripheral monocytes as well as a maintained
CEBPE-RETN proportion in these ex vivo models.
Importantly, human preadipocytes and isolated fat cells were
clearly devoid of RETN mRNA (Tables 2 and 4), similar to
endothelial cells, smooth muscle and many other non-myeloid
tissues, which have been tested [9,10,12,19–24,27,28]. Further-
more, the resistin release by adipose tissue is not due to adipose
cells [28,40]. Together, these data suggest that human resistin
should not be acknowledged as an adipose-secreted hormone but
as a specific myeloid-derived cytokine.
We also studied the murine genes Cebpe, Retn and Retnlg,
because the latter was found as a regulatory and functional
equivalent of human RETN [12]. Only Retn was detected in
adipose tissue of ob/ob mice and 3T3-L1 cells, whereas, in agree-
ment with other results [5–7,12], Cebpe and Retnlg expression
was observed in mouse peritoneal macrophages. However, very
little is known about similarities and differences between rodent
Retnlg and human RETN since only one study exists in the field
[12]. Obviously, lack of recognition of this fact is the basis of
a recent proposal of murine Retnlg and the non-existent human
RETNLG (Table 1) as a hormonal link between the digestive tract
and insulin resistance in both species [41]. Such conclusions only
create confusion. Also a presumed arthritogenic Retn-Retnlg
cross-function in mice [14] needs a further clarification.
Despite many RETN mRNA evaluations by real-time PCR,
different problems related to bioinformatic errors and test designs
exist [23,24]. In addition, conflicting Northern and SYBR Green
RT-PCR results [22] and lack of initial Ct values in most reports
make firm conclusions impossible. With the aim of having a gene
expression analysis as decisive as possible, we included the
impartial inter-laboratory reference TaqMan RT-PCR assays
from Applied Biosystems in parallel to our custom tests (Table 3).
They all demonstrated comparable outcomes over the entire
investigation also in the single-shot trial of three RETN assays
(Table 4), including the one that was reported to be successful in
the quantification of resistin mRNA in human adipocytes [15,16].
All three constructs detect a common sequence in full-length
RETN mRNA (Table 3) and the multiplexed assays have similar
detection efficiency (Table 4). A higher level of RETN transcript
was detected in inflamed synoviocytes in comparison to normal
PBMC. In contrast, no valid quantification could be made in
adipose and muscle samples by any of these optimized tests, as
indicated by both slope and R
2 values in Table 4. To obtain
Figure 1. Resistin Preferentially Induces Inflammatory Markers in Human WAT. Human WAT explants were incubated with 10 ng/ml TNF, white bars,
or 50 ng/ml resistin, grey bars, for 24 hrs and the fold change for several markers assessed by comparison with their level in basal cultures after
24 hrs. In A both gene (left) and protein (right) expressions of proinflammatory cytokines are shown, while B represents other inflammation-related
effects in WAT. C demonstrates different effects of TNF and resistin on markers of adipocyte differentiation. *, P,0.1; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0000031.g001
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[15,16,42,43] overloaded the cDNA to 115 ng in which a pro-
portion of 18S ribosomal RNA cannot be linearly distinguished
and, hence, the Ct of the internal reference can not normalize the
Ct of the tested gene. Under these conditions, the dCt figures
and the final quantity evaluations are, at best, conjectural
[15,16,42,43]. Taken together, we conclude that RETN is not
expressed in human isolated fat cells and that reports claiming
positive results have methodological shortcomings which have led
to spurious conclusions.
A proinflammatory nature of resistin has been suggested, but its
precise action in hepatocytes [28] and adipose tissue [24] is
unclear. We previously noticed that, in PBMC, resistin can induce
both gene expression and secretion of inflammatory cytokines like
IL6, IL8 and TNF of which only TNF, but not resistin, rapidly up-
regulates RETN [14]. Interestingly, lipopolysaccharide, a bacterial
endotoxin, controls RETN in the same, presumably TNF-
mediated, manner (unpublished data). Here we demonstrate that,
like in PBMC, resistin can also enhance the gene and protein
expression of IL6 and IL8 in human WAT, while the effect on
TNF mRNA expression was small. However, in contrast to the
well-known TNF-induced suppression of different adipose-specific
markers such as CEBPA, FABP4 and SLC2A4, these genes were
not affected by resistin at the concentration of 50 ng/ml. These
data concur with the unchanged insulin-stimulated glucose uptake
by human differentiated adipocytes treated with high concentra-
tions of recombinant resistin (58.5–5850 ng/ml) [24]. However,
McTernan et al. [42] reported that 0.1–50 ng of resistin impaired
the glucose incorporation into adipocytes. The cause for this
discrepancy is unclear.
We also found that resistin, similar to TNF, induces other
proinflammatory genes in human adipose tissue. Chemokine C-C
motif ligand 2 (CCL2) is a cytokine that displays chemotactic
activity for monocytes. Matrix metallopeptidase 3 (MMP3) may
affect the extracellular milieu of adipose tissue akin to that in
arthritis. Also PBEF1, pre-B-cell colony enhancing factor 1 or
visfatin, was activated by these cytokines. Both the basal and
resistin-stimulated gene expression profiles in WAT cultures bear
a remarkable resemblance to that seen in PBMC [14], but with
clear cell-type differences.
In conclusion, human fat cells do not express or secrete RETN
but WAT is evidently a target tissue for resistin. This finding,
together with the effect of resistin on PBMC, makes it clear that
resistin is an immune-derived systemic and locally acting
proinflammatory cytokine in man. However, in contrast to TNF,
it does not induce a rapid ‘‘dedifferentiation’’ of the adipose cells.
This variation is intriguing and obviously implicates that the
resistin intracellular signaling pathway is distinct from that of TNF
although both activate NFkB.
MATERIALS AND METHODS
Source of RNA and culture procedures
All biopsy procedures were approved by the Ethical Committee of
the Go ¨teborg University. Biopsies of human abdominal sub-
cutaneous adipose tissue were obtained from surgical operations
for nonsystemic abdominal disorders (mainly uterine extirpation,
gall bladder disease) from seven otherwise healthy and nonobese
females (BMI 26.161.8 kg/m2). The biopsies were cleaned of
blood and tissue debris, dissected into 10–20 mg explants and
incubated in medium 199 HANKS containing 1% human
albumin, 10mM HEPES, and 5.6 mM glucose according to
previously reported procedures [44]. WAT explants were cultured
with 10 ng/ml TNF (Sigma, UK) or 50 ng/ml human recombi-
nant RETN (PeproTech EC, UK) or without additives for 24 h.
The medium concentrations of the different cytokines were
measured with ELISA (R&D Systems, Minneapolis, MN, USA
and BioVendor, Czech Republic).
Preadipocytes were also obtained from the stromal vascular
fraction of biopsies of the abdominal subcutaneous WAT of non-
obese individuals. Another set of both omental and subcutaneous
adipose tissue biopsies were collected during surgical excision of
non-disseminated gastrointestinal cancers from 9 individuals (BMI
26.061.2 kg/m2) for the extraction of total RNA. PBMC were
isolated and stimulated by resistin and LPS as described [14]. The
PBMC fraction from a Lymphoprep density gradient consists of
mononuclear leukocytes, lymphocytes and less than 1% of
polymorphonuclear granulocytes. Synovial fluids from patients
with rheumatoid arthritis were centrifuged at 30006g for
10 minutes to pool monocytes, granulocytes, fibroblasts and other
cells collectively called synoviocytes. The monocytic cell line,
THP-1, was used as a standard of CEBPE, RETN and EMR1
gene expression at basal conditions. The RNA from human
macrophages was kindly provided by Dr. B. Staels (Lille, France).
Murine macrophages were acquired from peritoneal exudates of
BALB-C mice. Additional human skeletal muscle and isolated
mature adipocytes, also 3T3-L1 and mouse WAT samples have
been explained in past studies [9,44].
Real-time RT-PCR
All cellular samples were immediately subjected to the lysis buffer
and further processed with RNA extraction according to the
RNeasy Mini Kit manual (Qiagen, UK). Tissue specimens were
placed in RNA Later (Ambion, Austin, TX, USA) prior to a cell
disintegration by guanidinium thiocyanate followed by chloroform
extraction and final RNA purification via CsCl gradient
ultracentrifugation as described earlier [9]. Total RNA was
obtained from tissue and cell samples before and after culture.
RNA concentration and l 260/280 nm ratio was assessed and
complementary DNA synthesized according to the TaqManH
Reverse Transcription Reagents kit manual (Applied Biosystems,
Foster City, CA, USA) and loaded in each well at an amount
approximately equal to 5 ng total RNA. The gene expression was
measured with real-time RT-PCR (TaqMan
TM, Applied Biosys-
tems, Foster City, CA, USA) as previously described in detail [9].
Each custom TaqMan set, if possible, spans one or two exon
boundaries in order to facilitate both specificity of RNA detection
and efficiency of PCR (Table 3). Sequences were manually
designed and checked by means of the PrimerExpress
TM program
(Applied Biosystems) for the following parameters: secondary
structure, melting temperature, GC content, primer-primer and
primer-probe dimers. The NCBI GenBank database was used to
avoid all known sites of nucleotide polymorphism and unspecific
annealing of any oligonucleotide. Table 3 shows the PCR primer
positions in source mRNA sequences, which are close to the exon
junctions we used in our design. The indicated location in the
TaqManH Gene Expression Assay from Applied Biosystems is
exon boundary which is typically situated around the middle of the
TaqMan probe. Our custom sequences are available on request.
The real-time PCR tests were run as multiplexed, with
simultaneous detection in each well of both target transcript and
18S rRNA, an eukaryotic endogenous control, obtainable as
TaqManH Pre-Developed Assay Reagents (PDAR) for Gene
Expression, Applied Biosystems. Due to over 90% abundance of
18S rRNA in total cell RNA, the 18S rRNA PDAR has the primer
concentration limited from ordinary 900 nM to 150 nM with the
aim to delay very early amplification and to balance two parallel
polymerase chain reactions in a multiplexed assay. Nevertheless, as
Immune-Specific Human Resistin
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lesser 15, Ct values that are within the method’s default
background interval from cycle 3 to 15. Therefore, we optimized
(Table 4, Panel A) two PDARs specifically pre-mixed as reporter
VICH dye-labeled TaqManH, either; 1) non-fluorescent quencher
MGB, for minor groove binding, or; 2) fluorescent quencher
TAMRA
TM probes, each at restricted concentration 50 nM, with
a pair of unlabeled PCR primers, each further limited to 30 nM in
the reaction. The PDARs were, respectively, combined with; 1)
TaqManH Gene Expression Assay at the concentration of 250 nM
for FAM-MGB probe and 900 nM of each primer, and; 2) custom
constructs formulated as reporter FAM dye-labeled TAMRA dye-
quencher probe at 200 nM and both primers at 400 nM final
concentration. Comparative Ct and standard curve methods were
applied in that order for relative and absolute quantifications but
all results were presented as a fold change over the reference level
assessed as 1 or 100%.
Statistical analyses were carried out with Student’s t-test and P-
values of ,0.05 were considered significant.
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